FTC guidance – How to ensure your clinical integration programs pass antitrust muster
Abstract: The passage of the Patient Protection and Affordable Care Act (PPACA) and the increasing focus on efficiency and quality of care in the health care industry are prompting a growing number of hospitals to consider provider networks such as clinical integration programs (CIPs). While attractive, these networks have the potential to violate antitrust laws. This article discusses the Federal Trade Commission’s first advisory opinion regarding a CIP since the passage of the health care act. The guidance provides insight on how such programs can escape antitrust challenges.